Post-Translational Modifications of β-Amyloid as Targets for Precision Immunotherapy: From Molecular Features to Antibody Design

Abstract The key neuropathological hallmarks of Alzheimer’s disease (AD) are extracellular deposits of beta-amyloid (Aβ), neurofibrillary tangles composed of hyperphosphorylated tau protein, and progressive neurodegeneration. Approved therapeutic anti-Aβ monoclonal antibodies can reduce amyloid burden and moderately slow clinical decline at early stages of AD. One reason for the limited efficacy of this therapy may be the molecular heterogeneity of Aβ, which comprises a set of proteoforms differing in length, aggregation state, and the presence of molecular modifications. This review discusses structural Aβ proteoforms, alterations in amyloid precursor protein processing, molecular modifications of Aβ, and their contribution to aggregation and toxicity. Particular attention is paid to pathologically relevant proteoforms as promising targets for selective immunotherapy. The therapeutic relevance of such targets is determined not only by the presence of a chemical modification, but also by the aggregation state of Aβ, as well as its availability in brain tissue and the vascular wall. The review discusses approved anti-Aβ antibodies, experimental approaches to optimizing their specificity and delivery across the blood–brain barrier, and strategies for generating and humanizing antibodies against modified forms of Aβ. Neuroinflammation is considered separately as a therapeutic target and a potential component of combination treatment strategies. Current developments in AD therapy are likely to involve a transition from nonspecific removal of amyloid deposits toward more precise targeting of pathogenic Aβ proteoforms in combination with modulation of inflammatory mechanisms.

Authors

Institutions

Publication Details

Journal
Molecular Biology
Published
2026-11-18
DOI
https://doi.org/10.1134/s0026893326606385
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Post-Translational Modifications of β-Amyloid as Targets for Precision Immunotherapy: From Molecular Features to Antibody Design

Olga V. Britanova, Alexander А. Makarov, Dmitriy M. Chudakov, Irina Grigorova et al.
1 links
Molecular Biology
Alzheimer's disease research and treatments
article

Post-Translational Modifications of β-Amyloid as Targets for Precision Immunotherapy: From Molecular Features to Antibody Design

Olga V. Britanova, Alexander А. Makarov, Dmitriy M. Chudakov, Irina Grigorova, Sergey Lukyanov, L. A. Koltunova, E. M. Merzlyak, N. A. Nikolaev, M. A. Abdullaeva, V. A. Mitykevich
article en

Abstract

Abstract The key neuropathological hallmarks of Alzheimer’s disease (AD) are extracellular deposits of beta-amyloid (Aβ), neurofibrillary tangles composed of hyperphosphorylated tau protein, and progressive neurodegeneration. Approved therapeutic anti-Aβ monoclonal antibodies can reduce amyloid burden and moderately slow clinical decline at early stages of AD. One reason for the limited efficacy of this therapy may be the molecular heterogeneity of Aβ, which comprises a set of proteoforms differing in length, aggregation state, and the presence of molecular modifications. This review discusses structural Aβ proteoforms, alterations in amyloid precursor protein processing, molecular modifications of Aβ, and their contribution to aggregation and toxicity. Particular attention is paid to pathologically relevant proteoforms as promising targets for selective immunotherapy. The therapeutic relevance of such targets is determined not only by the presence of a chemical modification, but also by the aggregation state of Aβ, as well as its availability in brain tissue and the vascular wall. The review discusses approved anti-Aβ antibodies, experimental approaches to optimizing their specificity and delivery across the blood–brain barrier, and strategies for generating and humanizing antibodies against modified forms of Aβ. Neuroinflammation is considered separately as a therapeutic target and a potential component of combination treatment strategies. Current developments in AD therapy are likely to involve a transition from nonspecific removal of amyloid deposits toward more precise targeting of pathogenic Aβ proteoforms in combination with modulation of inflammatory mechanisms.

Molecular BiologyVol. 60(6)
Engelhardt Institute of Molecular Biology (RU), Russian Academy of Sciences (RU), Pirogov Russian National Research Medical University (RU), Institute of Bioorganic Chemistry (RU)
Ministry of Science and Higher Education of the Russian Federation
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon